Collaborative Drug Discovery
PureTech established the underlying programs and platforms that have resulted in a substantial pipeline comprised of 23 product candidates and one product cleared by the FDA that are being developed internally or by its affiliates.
View our corporate deck.
Internal R&D Programs
PureTech’s internal programs are focused on harnessing the lymphatic system and related immunology mechanisms for the treatment of cancer, immunological, lymphatic, and CNS-related disorders. The lymphatic system serves as a "superhighway" for immune cell trafficking, connects all tissues to regional lymph nodes and is essential for fluid balance.
Affiliate Programs
The affiliates includes 13 clinical-stage product candidates, including one product that has been cleared by the FDA and a second product candidate that has been filed with the FDA for review, and several other novel preclinical programs that have been developed in collaboration with some of the world's leading scientific experts.
Highlighted Programs
Ordered below by PureTech ownership; lines represent the most advanced stage of each product candidate; not comprehensive of preclinical and discovery programs.
Product Candidate**
PureTech Ownership
Initial Indications
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
100% (Internal)
Lymphedema
Initial Indication(s):
Lymphedema
Patient Population:
~1M
Collaborators:
Key Differentiation:
Product candidate for lymphedema with encouraging in-human pharmacokinetics
LYT-200
100% (Internal)
Solid Tumors, Autoimmune Disorders
Initial Indication(s):
Solid Tumors, Autoimmune Disorders
Patient Population:
Collaborators:
Key Differentiation:
LYT-200 is an investigational, fully human, IgG4 monoclonal antibody (mAb) that is designed to target galectin-9, a protein that regulates immunosuppression and is prominently expressed in hard-to-treat cancers such as colorectal cancer, or CRC, cholangiocarcinoma, pancreatic cancer and others.
LYT-210
100% (Internal)
Solid , Autoimmune Disorders
Initial Indication(s):
Solid tumors, autoimmune disorders
Patient Population:
Collaborators:
Key Differentiation:
PureTech is developing LYT-210, an investigational, fully human IgG1 monoclonal antibody (mAb) directed against the delta-1 (γδ1) chain of T cells bearing γδ1 T cell receptors (TCRs) for antibody dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).
ALV-306
82.7% (Alivio)
Distal Colistis, Pouchistis
Initial Indication(s):
Distal colitis, Pouchitis
Patient Population:
Distal colitis (~225K)
Pouchitis (70 – 135K)
Pouchitis (70 – 135K)
Collaborators:
Key Differentiation:
Alivio is pioneering targeted disease immunomodulation as a novel strategy to treat a range of chronic and acute inflammatory disorders. Its three preclinical-stage programs are in development for distal colitis and pouchitis, IBD, and IC/BPS.
ALV-304
82.7% (Alivio)
IBD
Initial Indication(s):
IBD
Patient Population:
~3M
Collaborators:
Key Differentiation:
Alivio is pioneering targeted disease immunomodulation as a novel strategy to treat a range of chronic and acute inflammatory disorders. Its three preclinical-stage programs are in development for distal colitis and pouchitis, IBD, and IC/BPS.
ALV-107
82.7% (Alivio)
IC/BPS
Initial Indication(s):
IC/BPS
Patient Population:
4 – 12M
Collaborators:
Key Differentiation:
Alivio is pioneering targeted disease immunomodulation as a novel strategy to treat a range of chronic and acute inflammatory disorders. Its three preclinical-stage programs are in development for distal colitis and pouchitis, IBD, and IC/BPS.
FOL-004
77.9% (Follica) R
Androgenic Alopecia
Initial Indication(s):
Androgenetic alopecia
Patient Population:
~90M
Collaborators:
Key Differentiation:
Follica is developing a regenerative biology platform designed to treat androgenetic alopecia, epithelial aging and other medical indications. Follica’s approach is based on generating an “embryonic window” in adults via a series of skin disruptions, stimulating stem cells causing new hair follicles to grow. It has two clinical-stage programs focusing on androgenetic alopecia and skin rejuvenation.
FOL-005
77.9% (Follica) R
Skin Rejuvenation
Initial Indication(s):
Skin Rejuvenation
Patient Population:
Collaborators:
Key Differentiation:
Follica is developing a regenerative biology platform designed to treat androgenetic alopecia, epithelial aging and other medical indications. Follica’s approach is based on generating an “embryonic window” in adults via a series of skin disruptions, stimulating stem cells causing new hair follicles to grow. It has two clinical-stage programs focusing on androgenetic alopecia and skin rejuvenation.
ENT-100
72.9% (Entrega)
Metabolic Disorders
Initial Indication(s):
Metabolic disorders
Patient Population:
Collaborators:
Key Differentiation:
Entrega is focused on the oral delivery of biologics, vaccines and other drugs that are otherwise not efficiently absorbed when taken orally. Entrega believes oral administration thus represents an ideal administration approach for this increasingly large class of therapies reshaping many areas of medicine, including the treatment of diabetes.
Sonde*
55.9% (Sonde)
Depression Screening
Initial Indication(s):
Depression Screening
Patient Population:
~17M
Collaborators:
Key Differentiation:
Sonde is developing a voice-based technology platform to measure health when a person speaks. Sonde’s proprietary technology is designed to sense and analyze subtle changes in the voice to create a range of persistent brain, muscle and respiratory health measurements that provide a more complete picture of health in just seconds.
VE303
53.3% (Vedanta)
rCDI
Initial Indication(s):
rCDI
Patient Population:
100 – 120K cases/yr
Collaborators:
Key Differentiation:
Vedanta is developing a new category of therapies for immune-mediated diseases based on a rationally defined consortia of human microbiome-derived bacteria. It has three clinical-stage programs and one preclinical program in development for rCDI, food allergy, IBD, and solid tumors.
VE202
53.3% (Vedanta)
IBD
Initial Indication(s):
IBD
Patient Population:
~3M
Collaborators:
Key Differentiation:
Vedanta is developing a new category of therapies for immune-mediated diseases based on a rationally defined consortia of human microbiome-derived bacteria. It has three clinical-stage programs and one preclinical program in development for rCDI, food allergy, IBD, and solid tumors.
VE416
53.3% (Vedanta)
Food Allergy
Initial Indication(s):
Food allergy
Patient Population:
~2.5M
Collaborators:
Key Differentiation:
Vedanta is developing a new category of therapies for immune-mediated diseases based on a rationally defined consortia of human microbiome-derived bacteria. It has three clinical-stage programs and one preclinical program in development for rCDI, food allergy, IBD, and solid tumors.
VE800
53.3% (Vedenta)
Solid Tumors
Initial Indication(s):
Solid tumors
Patient Population:
>67K cases/yr
Collaborators:
Key Differentiation:
Vedanta is developing a new category of therapies for immune-mediated diseases based on a rationally defined consortia of human microbiome-derived bacteria. It has three clinical-stage programs and one preclinical program in development for rCDI, food allergy, IBD, and solid tumors.
AKL-T02*
34.9% (Akili)
Autism
Initial Indication(s):
Autism
Patient Population:
~1.5M
Collaborators:
Key Differentiation:
Akili is pioneering the development of treatments designed to have direct therapeutic activity, delivered not through a traditional pill but via a high-quality video game experience. Akili has a broad pipeline of programs to target cognitive dysfunction associated with medical conditions across neurology and psychiatry. Akili is pursuing FDA clearance in the United States for its lead program in pediatric ADHD.
AKL-T03*
34.9% (Akili)
MDD, MS
Initial Indication(s):
MDD, MS
Patient Population:
MDD (~17M),
MS (~900K)
MS (~900K)
Collaborators:
Key Differentiation:
Akili is pioneering the development of treatments designed to have direct therapeutic activity, delivered not through a traditional pill but via a high-quality video game experience. Akili has a broad pipeline of programs to target cognitive dysfunction associated with medical conditions across neurology and psychiatry. Akili is pursuing FDA clearance in the United States for its lead program in pediatric ADHD.
AKL-T01*
34.9% (Akili)
Pediatric ADHD
Initial Indication(s):
Pediatric ADHD
Patient Population:
~6.4M
Collaborators:
Key Differentiation:
Akili is pioneering the development of treatments designed to have direct therapeutic activity, delivered not through a traditional pill but via a high-quality video game experience. Akili has a broad pipeline of programs to target cognitive dysfunction associated with medical conditions across neurology and psychiatry. Akili is pursuing FDA clearance in the United States for its lead program in pediatric ADHD.
AKL-T04*
34.9% (Akili)
MDD
Initial Indication(s):
MDD
Patient Population:
~17M
Collaborators:
Key Differentiation:
Akili is pioneering the development of treatments designed to have direct therapeutic activity, delivered not through a traditional pill but via a high-quality video game experience. Akili has a broad pipeline of programs to target cognitive dysfunction associated with medical conditions across neurology and psychiatry. Akili is pursuing FDA clearance in the United States for its lead program in pediatric ADHD.
VOR33
30.2% (Vor)
AML
Initial Indication(s):
AML
Patient Population:
~60K
Collaborators:
Key Differentiation:
Vor is taking a fundamentally novel approach for targeting cancer selectively by addressing the detrimental effects of on-target toxicity to healthy tissue. Vor is developing engineered hematopoietic stem cells, or eHSCs, for the treatment of hematological cancers.
PLENITY*
22.3% (Gelesis)
Overweight and Obesity
FDA Cleared
Initial Indication(s):
Overweight and obesity
Patient Population:
~150M US
Collaborators:
Key Differentiation:
Gelesis is developing oral therapeutics based on a novel, superabsorbent hydrogel technology platform to treat obesity and other chronic diseases related to the GI pathway. Gelesis’ proprietary approach is designed to act mechanically in the GI pathway to potentially alter the course of chronic diseases. Gelesis received clearance from the FDA for its first product, PLENITY (Gelesis100), and has additional programs in development for indications including NASH/NAFLD and CIC.
GS500*
22.3% (Gelesis)R
CIC
Initial Indication(s):
CIC
Patient Population:
~35M
Collaborators:
Key Differentiation:
Gelesis is developing oral therapeutics based on a novel, superabsorbent hydrogel technology platform to treat obesity and other chronic diseases related to the GI pathway. Gelesis’ proprietary approach is designed to act mechanically in the GI pathway to potentially alter the course of chronic diseases. Gelesis received clearance from the FDA for its first product, PLENITY (Gelesis100), and has additional programs in development for indications including NASH/NAFLD and CIC.
Gelesis200*
22.3% (Gelesis)R
Weight Management in T2D/Prediabetes
Initial Indication(s):
Weight management in T2D/prediabetes
Patient Population:
~114M
Collaborators:
Key Differentiation:
Gelesis is developing oral therapeutics based on a novel, superabsorbent hydrogel technology platform to treat obesity and other chronic diseases related to the GI pathway. Gelesis’ proprietary approach is designed to act mechanically in the GI pathway to potentially alter the course of chronic diseases. Gelesis received clearance from the FDA for its first product, PLENITY (Gelesis100), and has additional programs in development for indications including NASH/NAFLD and CIC.
GS300*
22.3% (Gelesis)R
NASH/NAFLD
Initial Indication(s):
NASH/NAFLD
Patient Population:
80 – 100M
Collaborators:
Key Differentiation:
Gelesis is developing oral therapeutics based on a novel, superabsorbent hydrogel technology platform to treat obesity and other chronic diseases related to the GI pathway. Gelesis’ proprietary approach is designed to act mechanically in the GI pathway to potentially alter the course of chronic diseases. Gelesis received clearance from the FDA for its first product, PLENITY (Gelesis100), and has additional programs in development for indications including NASH/NAFLD and CIC.
GS400*
22.3% (Gelesis)R
IBD
Initial Indication(s):
IBD
Patient Population:
~3M
Collaborators:
Key Differentiation:
Gelesis is developing oral therapeutics based on a novel, superabsorbent hydrogel technology platform to treat obesity and other chronic diseases related to the GI pathway. Gelesis’ proprietary approach is designed to act mechanically in the GI pathway to potentially alter the course of chronic diseases. Gelesis received clearance from the FDA for its first product, PLENITY (Gelesis100), and has additional programs in development for indications including NASH/NAFLD and CIC.
KarXT
20.4% (Karuna)R
Schizophrenia, Dementia-related psychosis, Pain
Initial Indication(s):
Schizophrenia, Dementia-related psychosis, Pain
Patient Population:
Schizophrenia (~2.7M),
Dementia-related Psychosis (~1.2M),
Pain
Dementia-related Psychosis (~1.2M),
Pain
Collaborators:
Key Differentiation:
Karuna is targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across CNS disorders., including schizophrenia and psychosis in AD, as well as pain. Its lead program is expected to enter a Phase 3 study.
Note: Lines represent the most advanced stage of each product candidate; not comprehensive of preclinical programs.
* Relevant ownership interests for affiliate programs were calculated on a diluted basis (as opposed to a voting basis) as of 30 June 2019 (other than Follica which is as of 19 July 2019, Vedanta which is as of 23 September 2019, and Gelesis which is as of 9 December 2019) including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Vor ownership assumes all future tranches are funded in the Series A financing round, with PureTech investing an additional $0.7 million, Sonde ownership assumes all future tranches are funded in the Series A financing round, and Gelesis ownership assumes all committed tranches are funded in the Series 3 Growth financing round. Karuna ownership is shown on an outstanding share basis, calculated as of 22 January 2020. With respect to internal programs, PureTech owns 100% of LYT-100, and PureTech owns 100% of LYT-200 and LYT-210 subject to certain interests held by the inventors and advisors to those programs.
R PureTech Health has a right to royalty payments as a percentage of net sales
* These product candidates are regulated as devices and their development has been approximately equated to phases of clinical development
** PureTech is not responsible for development of all of these product candidates and FDA-cleared product. For example: Certain of our Affiliates, including Akili, Vor, Karuna, Gelesis, Follica and Vedanta have independent development teams and PureTech does not control the day-to-day development of their respective product candidates. However, with respect to Follica and Vedanta, we exert control through majority stock ownership, board representation, and voting decisions.
LYT-100
Lymphedema
100% (Internal)
Phase 1
Initial Indication(s):
Lymphedema
Patient Population:
~1M
Collaborators:
Key Differentiation:
Product candidate for lymphedema with encouraging in-human pharmacokinetics
LYT-200
Solid Tumors, Autoimmune Disorders
100% (Internal)
Preclinical
Initial Indication(s):
Solid Tumors, Autoimmune Disorders
Patient Population:
Collaborators:
Key Differentiation:
LYT-200 is an investigational, fully human, IgG4 monoclonal antibody (mAb) that is designed to target galectin-9, a protein that regulates immunosuppression and is prominently expressed in hard-to-treat cancers such as colorectal cancer, or CRC, cholangiocarcinoma, pancreatic cancer and others.
LYT-210
Solid , Autoimmune Disorders
100% (Internal)
Preclinical
Initial Indication(s):
Solid tumors, autoimmune disorders
Patient Population:
Collaborators:
Key Differentiation:
PureTech is developing LYT-210, an investigational, fully human IgG1 monoclonal antibody (mAb) directed against the delta-1 (γδ1) chain of T cells bearing γδ1 T cell receptors (TCRs) for antibody dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).
ALV-306
Distal Colistis, Pouchistis
82.7% (Alivio)
Preclinical
Initial Indication(s):
Distal colitis, Pouchitis
Patient Population:
Distal colitis (~225K)
Pouchitis (70 – 135K)
Pouchitis (70 – 135K)
Collaborators:
Key Differentiation:
Alivio is pioneering targeted disease immunomodulation as a novel strategy to treat a range of chronic and acute inflammatory disorders. Its three preclinical-stage programs are in development for distal colitis and pouchitis, IBD, and IC/BPS.
ALV-304
IBD
82.7% (Alivio)
Preclinical
Initial Indication(s):
IBD
Patient Population:
~3M
Collaborators:
Key Differentiation:
Alivio is pioneering targeted disease immunomodulation as a novel strategy to treat a range of chronic and acute inflammatory disorders. Its three preclinical-stage programs are in development for distal colitis and pouchitis, IBD, and IC/BPS.
ALV-107
IC/BPS
82.7% (Alivio)
Preclinical
Initial Indication(s):
IC/BPS
Patient Population:
4 – 12M
Collaborators:
Key Differentiation:
Alivio is pioneering targeted disease immunomodulation as a novel strategy to treat a range of chronic and acute inflammatory disorders. Its three preclinical-stage programs are in development for distal colitis and pouchitis, IBD, and IC/BPS.
FOL-004
Androgenic Alopecia
77.9% (Follica) R
Phase 2
Initial Indication(s):
Androgenetic alopecia
Patient Population:
~90M
Collaborators:
Key Differentiation:
Follica is developing a regenerative biology platform designed to treat androgenetic alopecia, epithelial aging and other medical indications. Follica’s approach is based on generating an “embryonic window” in adults via a series of skin disruptions, stimulating stem cells causing new hair follicles to grow. It has two clinical-stage programs focusing on androgenetic alopecia and skin rejuvenation.
FOL-005
Skin Rejuvenation
77.9% (Follica) R
Phase 2
Initial Indication(s):
Skin Rejuvenation
Patient Population:
Collaborators:
Key Differentiation:
Follica is developing a regenerative biology platform designed to treat androgenetic alopecia, epithelial aging and other medical indications. Follica’s approach is based on generating an “embryonic window” in adults via a series of skin disruptions, stimulating stem cells causing new hair follicles to grow. It has two clinical-stage programs focusing on androgenetic alopecia and skin rejuvenation.
ENT-100
Metabolic Disorders
72.9% (Entrega)
Preclinical
Initial Indication(s):
Metabolic disorders
Patient Population:
Collaborators:
Key Differentiation:
Entrega is focused on the oral delivery of biologics, vaccines and other drugs that are otherwise not efficiently absorbed when taken orally. Entrega believes oral administration thus represents an ideal administration approach for this increasingly large class of therapies reshaping many areas of medicine, including the treatment of diabetes.
Sonde*
Depression Screening
55.9% (Sonde)
Phase 1
Initial Indication(s):
Depression Screening
Patient Population:
~17M
Collaborators:
Key Differentiation:
Sonde is developing a voice-based technology platform to measure health when a person speaks. Sonde’s proprietary technology is designed to sense and analyze subtle changes in the voice to create a range of persistent brain, muscle and respiratory health measurements that provide a more complete picture of health in just seconds.
VE303
rCDI
53.3% (Vedanta)
Phase 2
Initial Indication(s):
rCDI
Patient Population:
100 – 120K cases/yr
Collaborators:
Key Differentiation:
Vedanta is developing a new category of therapies for immune-mediated diseases based on a rationally defined consortia of human microbiome-derived bacteria. It has three clinical-stage programs and one preclinical program in development for rCDI, food allergy, IBD, and solid tumors.
VE202
IBD
53.3% (Vedanta)
Phase 1
Initial Indication(s):
IBD
Patient Population:
~3M
Collaborators:
Key Differentiation:
Vedanta is developing a new category of therapies for immune-mediated diseases based on a rationally defined consortia of human microbiome-derived bacteria. It has three clinical-stage programs and one preclinical program in development for rCDI, food allergy, IBD, and solid tumors.
VE416
Food Allergy
53.3% (Vedanta)
Phase 1
Initial Indication(s):
Food allergy
Patient Population:
~2.5M
Collaborators:
Key Differentiation:
Vedanta is developing a new category of therapies for immune-mediated diseases based on a rationally defined consortia of human microbiome-derived bacteria. It has three clinical-stage programs and one preclinical program in development for rCDI, food allergy, IBD, and solid tumors.
VE800
Solid Tumors
53.3% (Vedenta)
Phase 1
Initial Indication(s):
Solid tumors
Patient Population:
>67K cases/yr
Collaborators:
Key Differentiation:
Vedanta is developing a new category of therapies for immune-mediated diseases based on a rationally defined consortia of human microbiome-derived bacteria. It has three clinical-stage programs and one preclinical program in development for rCDI, food allergy, IBD, and solid tumors.
AKL-T02*
Autism
34.9% (Akili)
Phase 2
Initial Indication(s):
Autism
Patient Population:
~1.5M
Collaborators:
Key Differentiation:
Akili is pioneering the development of treatments designed to have direct therapeutic activity, delivered not through a traditional pill but via a high-quality video game experience. Akili has a broad pipeline of programs to target cognitive dysfunction associated with medical conditions across neurology and psychiatry. Akili is pursuing FDA clearance in the United States for its lead program in pediatric ADHD.
AKL-T03*
MDD, MS
34.9% (Akili)
Phase 2
Initial Indication(s):
MDD, MS
Patient Population:
MDD (~17M),
MS (~900K)
MS (~900K)
Collaborators:
Key Differentiation:
Akili is pioneering the development of treatments designed to have direct therapeutic activity, delivered not through a traditional pill but via a high-quality video game experience. Akili has a broad pipeline of programs to target cognitive dysfunction associated with medical conditions across neurology and psychiatry. Akili is pursuing FDA clearance in the United States for its lead program in pediatric ADHD.
AKL-T01*
Pediatric ADHD
34.9% (Akili)
Phase 3
Initial Indication(s):
Pediatric ADHD
Patient Population:
~6.4M
Collaborators:
Key Differentiation:
Akili is pioneering the development of treatments designed to have direct therapeutic activity, delivered not through a traditional pill but via a high-quality video game experience. Akili has a broad pipeline of programs to target cognitive dysfunction associated with medical conditions across neurology and psychiatry. Akili is pursuing FDA clearance in the United States for its lead program in pediatric ADHD.
AKL-T04*
MDD
34.9% (Akili)
Preclinical
Initial Indication(s):
MDD
Patient Population:
~17M
Collaborators:
Key Differentiation:
Akili is pioneering the development of treatments designed to have direct therapeutic activity, delivered not through a traditional pill but via a high-quality video game experience. Akili has a broad pipeline of programs to target cognitive dysfunction associated with medical conditions across neurology and psychiatry. Akili is pursuing FDA clearance in the United States for its lead program in pediatric ADHD.
VOR33
AML
30.2% (Vor)
Preclinical
Initial Indication(s):
AML
Patient Population:
~60K
Collaborators:
Key Differentiation:
Vor is taking a fundamentally novel approach for targeting cancer selectively by addressing the detrimental effects of on-target toxicity to healthy tissue. Vor is developing engineered hematopoietic stem cells, or eHSCs, for the treatment of hematological cancers.
PLENITY*
Overweight and Obesity
22.3% (Gelesis)
Phase 3
FDA Cleared
Initial Indication(s):
Overweight and obesity
Patient Population:
~150M US
Collaborators:
Key Differentiation:
Gelesis is developing oral therapeutics based on a novel, superabsorbent hydrogel technology platform to treat obesity and other chronic diseases related to the GI pathway. Gelesis’ proprietary approach is designed to act mechanically in the GI pathway to potentially alter the course of chronic diseases. Gelesis received clearance from the FDA for its first product, PLENITY (Gelesis100), and has additional programs in development for indications including NASH/NAFLD and CIC.
GS500*
CIC
22.3% (Gelesis)R
Phase 2
Initial Indication(s):
CIC
Patient Population:
~35M
Collaborators:
Key Differentiation:
Gelesis is developing oral therapeutics based on a novel, superabsorbent hydrogel technology platform to treat obesity and other chronic diseases related to the GI pathway. Gelesis’ proprietary approach is designed to act mechanically in the GI pathway to potentially alter the course of chronic diseases. Gelesis received clearance from the FDA for its first product, PLENITY (Gelesis100), and has additional programs in development for indications including NASH/NAFLD and CIC.
Gelesis200*
Weight Management in T2D/Prediabetes
22.3% (Gelesis)R
Phase 2
Initial Indication(s):
Weight management in T2D/prediabetes
Patient Population:
~114M
Collaborators:
Key Differentiation:
Gelesis is developing oral therapeutics based on a novel, superabsorbent hydrogel technology platform to treat obesity and other chronic diseases related to the GI pathway. Gelesis’ proprietary approach is designed to act mechanically in the GI pathway to potentially alter the course of chronic diseases. Gelesis received clearance from the FDA for its first product, PLENITY (Gelesis100), and has additional programs in development for indications including NASH/NAFLD and CIC.
GS300*
NASH/NAFLD
22.3% (Gelesis)R
Preclinical
Initial Indication(s):
NASH/NAFLD
Patient Population:
80 – 100M
Collaborators:
Key Differentiation:
Gelesis is developing oral therapeutics based on a novel, superabsorbent hydrogel technology platform to treat obesity and other chronic diseases related to the GI pathway. Gelesis’ proprietary approach is designed to act mechanically in the GI pathway to potentially alter the course of chronic diseases. Gelesis received clearance from the FDA for its first product, PLENITY (Gelesis100), and has additional programs in development for indications including NASH/NAFLD and CIC.
GS400*
IBD
22.3% (Gelesis)R
Preclinical
Initial Indication(s):
IBD
Patient Population:
~3M
Collaborators:
Key Differentiation:
Gelesis is developing oral therapeutics based on a novel, superabsorbent hydrogel technology platform to treat obesity and other chronic diseases related to the GI pathway. Gelesis’ proprietary approach is designed to act mechanically in the GI pathway to potentially alter the course of chronic diseases. Gelesis received clearance from the FDA for its first product, PLENITY (Gelesis100), and has additional programs in development for indications including NASH/NAFLD and CIC.
KarXT
Schizophrenia, Dementia-related psychosis, Pain
20.4% (Karuna)R
Phase 2
Initial Indication(s):
Schizophrenia, Dementia-related psychosis, Pain
Patient Population:
Schizophrenia (~2.7M),
Dementia-related Psychosis (~1.2M),
Pain
Dementia-related Psychosis (~1.2M),
Pain
Collaborators:
Key Differentiation:
Karuna is targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across CNS disorders., including schizophrenia and psychosis in AD, as well as pain. Its lead program is expected to enter a Phase 3 study.
The BIG Idea - Moving medicine forward at PureTech
Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out
Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out
